Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

The conversation discusses hair loss treatments, focusing on the anti-androgen component CB 03 01 and its systemic absorption and safety compared to finasteride. It highlights concerns about inhibiting DHT conversion and the safety of using clascoterone for hair loss.

A user is considering trying Man Matters' new Minoxifin Advanced, which combines minoxidil and finasteride with "cetosomal technology" for better absorption, but is unsure if it's worth the higher price. Another user criticizes the brand, but the original poster finds it suitable for their scalp without irritation.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The conversation discusses using a 4-in-1 spray containing minoxidil, tretinoin, caffeine, and melatonin for hair loss. Users consider the potential benefits of combining these ingredients, with some interest in a comprehensive approach to treatment.

A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

The user experienced noticeable hair regrowth in three months using finasteride, minoxidil, and weekly dermastamping, while managing scalp inflammation with clobetasol. The user also uses a sea salt shampoo and rosemary conditioner to help maintain scalp health.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The user is three months into using topical finasteride, minoxidil, and tretinoin for hair loss, noticing slight improvement in hair density. They plan to continue treatment and expect more visible results between 6 to 9 months, with the goal of stabilizing hair loss and possibly achieving some regrowth.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The conversation discusses a user's three-month progress using Minoxidil and finasteride for hair loss. Users suggest shaving for better comparison and mention adding topical dutasteride.

Mixing clascoterone with minoxidil involves using 99% ethanol and propylene glycol. Users discuss the effectiveness and potential side effects of this DIY solution.

The user has been using finasteride, minoxidil, and a derma stamp for hair loss for nearly three months and is considering adding tretinoin. They are advised to be patient, as results typically take 6-12 months, and are exploring other options like oral minoxidil and dutasteride.

A 28-year-old male experienced hair regrowth using a topical spray containing minoxidil, finasteride, and tretinoin, along with occasional microneedling, after stopping oral finasteride due to side effects. He is pleased with the progress after three months and plans to continue using the spray.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

A 23-year-old male with early stage 4 hair loss is using a treatment routine that includes minoxidil 5% with tretinoin once daily, finasteride 1mg every other day, 2.5mg oral minoxidil every other day, and derma rolling twice a week. The discussion is about whether using minoxidil twice a day is better than combining it with tretinoin once a day.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses hair loss treatments, specifically finasteride, for a 21-year-old FTM individual concerned about hairline recession. Users suggest finasteride and possibly topical minoxidil, while noting potential side effects like menstrual cycle return and brain fog.

A 21-year-old male shares a 3-month progress update using 1 mg oral finasteride daily and 5% topical minoxidil twice daily, reporting no side effects and noticeable hair growth. Users commend the results and encourage continuation of the treatment.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user is starting a hair loss treatment with a 3-in-1 spray containing 6% minoxidil, 0.3% finasteride, and 0.025% tretinoin. Users are skeptical about its effectiveness due to advanced hair loss, but some suggest adding microneedling and using affordable generics.